Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,481,609

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 4:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business. However, high debt level remains a woe.

    Quest Diagnostics (DGX) Acquires Florida-Based NLS Assets

    by Zacks Equity Research

    Quest Diagnostics (DGX) expects the acquisition to broaden the company's spectrum in diagnostic innovation and insights.

      Here's Why You Should Retain Masimo (MASI) Stock For Now

      by Zacks Equity Research

      Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

      Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

      by Zacks Equity Research

      Investors are optimistic about Thermo Fisher (TMO) on robust segmental growth and raised 2021 guidance.

      Here's Why You Should Hold on to NextGen (NXGN) Stock Now

      by Zacks Equity Research

      NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.

      Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study

      by Zacks Equity Research

      Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.

      Here's Why You Should Retain PacBio (PACB) Stock For Now

      by Zacks Equity Research

      Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.

      Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic

      by Zacks Equity Research

      Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.

      Bruker (BRKR) Hits a New 52-Week High: What's Driving It?

      by Zacks Equity Research

      Investors are optimistic about Bruker (BRKR) on solid BSI Nano Group growth potential and raised 2021 financial guidance.

      Here's Why You Should Invest in West Pharmaceutical (WST) Now

      by Zacks Equity Research

      West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

      Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion

      by Zacks Equity Research

      Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.

      Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

      by Zacks Equity Research

      Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.

      Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?

      by Zacks Equity Research

      Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.

      LabCorp (LH) Inks Deal to Assess Disparities in Drug Development

      by Zacks Equity Research

      LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.

      Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag

      by Zacks Equity Research

      Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.

      Here's Why You Should Retain Cooper Companies (COO) Stock Now

      by Zacks Equity Research

      Cooper Companies (COO) continues to benefit from strength in its business segments.

      Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?

      by Zacks Equity Research

      Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.

      ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization

      by Zacks Equity Research

      ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.

      West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?

      by Zacks Equity Research

      Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.

      Here's Why You Should Hold on to LHC Group (LHCG) Stock Now

      by Zacks Equity Research

      LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.

      Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study

      by Zacks Equity Research

      Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.

      Merit Medical (MMSI) Expands Drainage Portfolio With New Product

      by Zacks Equity Research

      Merit Medical's (MMSI) new commercial product launch can make sample collection simple, safe and efficient.

      Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

      by Zacks Equity Research

      Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

      OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout

      by Zacks Equity Research

      OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.

      ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?

      by Zacks Equity Research

      Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.